DK2704800T3 - PROCEDURES FOR Predicting the development of complement-mediated disease - Google Patents
PROCEDURES FOR Predicting the development of complement-mediated disease Download PDFInfo
- Publication number
- DK2704800T3 DK2704800T3 DK12776262.3T DK12776262T DK2704800T3 DK 2704800 T3 DK2704800 T3 DK 2704800T3 DK 12776262 T DK12776262 T DK 12776262T DK 2704800 T3 DK2704800 T3 DK 2704800T3
- Authority
- DK
- Denmark
- Prior art keywords
- subject
- haplotypes
- complement
- haplotype
- snps
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title claims description 344
- 238000000034 method Methods 0.000 title claims description 214
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 276
- 201000010099 disease Diseases 0.000 title description 265
- 230000001404 mediated effect Effects 0.000 title description 227
- 238000011161 development Methods 0.000 title description 26
- 102000054766 genetic haplotypes Human genes 0.000 claims description 811
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 367
- 208000002780 macular degeneration Diseases 0.000 claims description 355
- 238000012217 deletion Methods 0.000 claims description 127
- 230000037430 deletion Effects 0.000 claims description 125
- 238000011282 treatment Methods 0.000 claims description 125
- 102100035432 Complement factor H Human genes 0.000 claims description 64
- 238000011321 prophylaxis Methods 0.000 claims description 25
- 102210014998 rs3753395 Human genes 0.000 claims description 20
- 102220005751 rs2274700 Human genes 0.000 claims description 18
- 102220130080 rs3753396 Human genes 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 3
- 102100029058 Coagulation factor XIII B chain Human genes 0.000 claims 2
- 101000918350 Homo sapiens Coagulation factor XIII B chain Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 description 427
- 102220592822 Complement factor H_Y402H_mutation Human genes 0.000 description 143
- 102200031793 rs800292 Human genes 0.000 description 130
- 108700028369 Alleles Proteins 0.000 description 75
- 108010053085 Complement Factor H Proteins 0.000 description 75
- 230000001681 protective effect Effects 0.000 description 73
- 230000003247 decreasing effect Effects 0.000 description 65
- 230000007935 neutral effect Effects 0.000 description 55
- 238000004458 analytical method Methods 0.000 description 49
- 108090000623 proteins and genes Proteins 0.000 description 46
- 230000000670 limiting effect Effects 0.000 description 45
- 239000000523 sample Substances 0.000 description 43
- 210000000349 chromosome Anatomy 0.000 description 42
- 101000890732 Homo sapiens Complement factor H-related protein 1 Proteins 0.000 description 41
- 102100035321 Complement factor H-related protein 3 Human genes 0.000 description 40
- 101000878136 Homo sapiens Complement factor H-related protein 3 Proteins 0.000 description 40
- 238000003556 assay Methods 0.000 description 38
- 102100040132 Complement factor H-related protein 1 Human genes 0.000 description 35
- 102000054765 polymorphisms of proteins Human genes 0.000 description 32
- 150000007523 nucleic acids Chemical class 0.000 description 29
- 239000002773 nucleotide Substances 0.000 description 29
- 125000003729 nucleotide group Chemical group 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 28
- 102000039446 nucleic acids Human genes 0.000 description 28
- 230000018109 developmental process Effects 0.000 description 25
- 230000002068 genetic effect Effects 0.000 description 25
- 239000003550 marker Substances 0.000 description 22
- 102220005752 rs1410996 Human genes 0.000 description 22
- 238000003753 real-time PCR Methods 0.000 description 19
- 238000003205 genotyping method Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 238000012216 screening Methods 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- 229920001184 polypeptide Polymers 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 11
- 102100035325 Complement factor H-related protein 5 Human genes 0.000 description 10
- 101000878134 Homo sapiens Complement factor H-related protein 5 Proteins 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000012014 optical coherence tomography Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 8
- 108091093088 Amplicon Proteins 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000024203 complement activation Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 102100035326 Complement factor H-related protein 2 Human genes 0.000 description 7
- 208000008069 Geographic Atrophy Diseases 0.000 description 7
- 101000878135 Homo sapiens Complement factor H-related protein 2 Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 238000010200 validation analysis Methods 0.000 description 7
- 102000016550 Complement Factor H Human genes 0.000 description 6
- 102100035324 Complement factor H-related protein 4 Human genes 0.000 description 6
- 101000878133 Homo sapiens Complement factor H-related protein 4 Proteins 0.000 description 6
- 108091008109 Pseudogenes Proteins 0.000 description 6
- 102000057361 Pseudogenes Human genes 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000007477 logistic regression Methods 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 5
- 108090000621 Ribonuclease P Proteins 0.000 description 5
- 102000004167 Ribonuclease P Human genes 0.000 description 5
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 208000022401 dense deposit disease Diseases 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 4
- 102210014988 rs10737680 Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- 108700005075 Regulator Genes Proteins 0.000 description 3
- 241000239226 Scorpiones Species 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000003066 decision tree Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 230000033607 mismatch repair Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 208000011511 primary membranoproliferative glomerulonephritis Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101150030967 CFH gene Proteins 0.000 description 2
- 101150077755 CFHR3 gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 108090000955 Complement C2 Proteins 0.000 description 2
- 102000004381 Complement C2 Human genes 0.000 description 2
- 108090000056 Complement factor B Proteins 0.000 description 2
- 102000003712 Complement factor B Human genes 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 101150059585 F13B gene Proteins 0.000 description 2
- 206010055690 Foetal death Diseases 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 description 2
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 2
- 206010019860 Hereditary angioedema Diseases 0.000 description 2
- 101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 description 2
- 208000031814 IgA Vasculitis Diseases 0.000 description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 2
- 206010021263 IgA nephropathy Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 2
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100334029 Mus musculus F13b gene Proteins 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 238000002944 PCR assay Methods 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003460 anti-nuclear Effects 0.000 description 2
- 230000002137 anti-vascular effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000013398 bayesian method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108091008053 gene clusters Proteins 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 238000002577 ophthalmoscopy Methods 0.000 description 2
- 206010053857 partial lipodystrophy Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 239000013643 reference control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 102200031812 rs1065489 Human genes 0.000 description 2
- 102210014994 rs10922106 Human genes 0.000 description 2
- 102210039666 rs1329428 Human genes 0.000 description 2
- 102210048021 rs6677604 Human genes 0.000 description 2
- 102210039659 rs7535263 Human genes 0.000 description 2
- 102210039667 rs7540032 Human genes 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000004412 visual outcomes Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- BDBMLMBYCXNVMC-UHFFFAOYSA-O 4-[(2e)-2-[(2e,4e,6z)-7-[1,1-dimethyl-3-(4-sulfobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS(O)(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C BDBMLMBYCXNVMC-UHFFFAOYSA-O 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 101150058502 Acaca gene Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100038568 Age-related maculopathy susceptibility protein 2 Human genes 0.000 description 1
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 101150083730 CFHR1 gene Proteins 0.000 description 1
- 241001494315 Cacatuidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000700112 Chinchilla Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 101000808726 Homo sapiens Age-related maculopathy susceptibility protein 2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101000720907 Pseudomonas savastanoi pv. phaseolicola Ornithine carbamoyltransferase 1, anabolic Proteins 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- 101150039984 RCA gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000041877 UGRP family Human genes 0.000 description 1
- 108091079697 UGRP family Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000012042 bayesian logistic regression model Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940105784 coagulation factor xiii Drugs 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002571 electroretinography Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000013534 fluorescein angiography Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 238000003331 infrared imaging Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000003333 near-infrared imaging Methods 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 102220032377 rs104895252 Human genes 0.000 description 1
- 102200103620 rs121908920 Human genes 0.000 description 1
- 102210034458 rs419137 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/50—Detection characterised by immobilisation to a surface
- C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480929P | 2011-04-29 | 2011-04-29 | |
| PCT/US2012/035467 WO2012149329A2 (en) | 2011-04-29 | 2012-04-27 | Methods of predicting the development of complement-mediated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2704800T3 true DK2704800T3 (en) | 2019-01-14 |
Family
ID=47073084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12776262.3T DK2704800T3 (en) | 2011-04-29 | 2012-04-27 | PROCEDURES FOR Predicting the development of complement-mediated disease |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20140357732A1 (enExample) |
| EP (1) | EP2704800B1 (enExample) |
| JP (1) | JP2014513958A (enExample) |
| KR (1) | KR20140074258A (enExample) |
| CN (1) | CN103874526A (enExample) |
| AU (1) | AU2012249521A1 (enExample) |
| BR (1) | BR112013027851A2 (enExample) |
| CA (1) | CA2834676A1 (enExample) |
| DK (1) | DK2704800T3 (enExample) |
| SG (1) | SG194235A1 (enExample) |
| WO (1) | WO2012149329A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| JP6829878B2 (ja) * | 2017-03-10 | 2021-02-17 | 国立大学法人浜松医科大学 | 加齢黄斑変性の発症リスクの評価方法 |
| WO2020019002A1 (en) | 2018-07-20 | 2020-01-23 | University Of Utah Research Foundation | Gene therapy for macular degeneration |
| KR102333953B1 (ko) * | 2020-07-10 | 2021-12-02 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 유전자 마커 |
| US12518859B2 (en) * | 2023-07-26 | 2026-01-06 | Helix, Inc. | Systems and methods for providing test results of gene sequencing data on a recurring basis |
| CN119694384B (zh) * | 2024-12-03 | 2025-10-03 | 南京医科大学 | 基于汇总统计数据的复杂性状关联基因检测方法及系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| WO2006096561A2 (en) * | 2005-03-04 | 2006-09-14 | Duke University | Genetic variants increase the risk of age-related macular degeneration |
| DK2447275T3 (en) * | 2006-07-13 | 2015-06-29 | Univ Iowa Res Found | Methods and reagents for the treatment of age-related macular degeneration |
| WO2009059317A2 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Predicting amd with snps within or near c2, factor b, plekha1, htra1, prelp, or loc387715 |
| US8114592B2 (en) * | 2008-03-18 | 2012-02-14 | Cambridge Enterprise Limited | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof |
| WO2010075519A2 (en) * | 2008-12-23 | 2010-07-01 | Massachusetts Eye & Ear Infirmary | Allelic variants associated with advanced age-related macular degeneration |
| US20120202708A1 (en) * | 2010-10-14 | 2012-08-09 | Sequenom, Inc. | Complement factor h copy number variants found in the rca locus |
| WO2012082912A2 (en) * | 2010-12-14 | 2012-06-21 | Tufts Medical Center, Inc. | Markers related to age-related macular degeneration and uses therefor |
| BR112013023724A2 (pt) * | 2011-03-15 | 2019-09-24 | Univ Utah Res Found | métodos para tratar doença ou sintoma, detriagem para um agente ou uma combinação de agentes, e para determinar a eficácia de um agente e de um tratamento |
| EP2895624B1 (en) * | 2012-09-14 | 2022-06-01 | University Of Utah Research Foundation | Methods of predicting the development of amd based on chromosome 1 and chromosome 10 |
| US9896728B2 (en) * | 2013-01-29 | 2018-02-20 | Arcticrx Ltd. | Method for determining a therapeutic approach for the treatment of age-related macular degeneration (AMD) |
-
2012
- 2012-04-27 KR KR1020137031638A patent/KR20140074258A/ko not_active Withdrawn
- 2012-04-27 DK DK12776262.3T patent/DK2704800T3/en active
- 2012-04-27 JP JP2014508602A patent/JP2014513958A/ja active Pending
- 2012-04-27 CA CA2834676A patent/CA2834676A1/en not_active Abandoned
- 2012-04-27 EP EP12776262.3A patent/EP2704800B1/en active Active
- 2012-04-27 BR BR112013027851A patent/BR112013027851A2/pt not_active IP Right Cessation
- 2012-04-27 US US14/114,751 patent/US20140357732A1/en not_active Abandoned
- 2012-04-27 SG SG2013080502A patent/SG194235A1/en unknown
- 2012-04-27 WO PCT/US2012/035467 patent/WO2012149329A2/en not_active Ceased
- 2012-04-27 CN CN201280031235.6A patent/CN103874526A/zh active Pending
- 2012-04-27 AU AU2012249521A patent/AU2012249521A1/en not_active Abandoned
-
2017
- 2017-06-27 US US15/634,892 patent/US20180155788A1/en not_active Abandoned
-
2020
- 2020-01-03 US US16/734,168 patent/US20200239958A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG194235A1 (en) | 2013-12-30 |
| US20180155788A1 (en) | 2018-06-07 |
| CA2834676A1 (en) | 2012-11-01 |
| EP2704800A4 (en) | 2015-04-29 |
| AU2012249521A1 (en) | 2013-11-14 |
| EP2704800B1 (en) | 2018-09-12 |
| US20200239958A1 (en) | 2020-07-30 |
| EP2704800A2 (en) | 2014-03-12 |
| US20140357732A1 (en) | 2014-12-04 |
| WO2012149329A2 (en) | 2012-11-01 |
| KR20140074258A (ko) | 2014-06-17 |
| WO2012149329A3 (en) | 2012-12-20 |
| JP2014513958A (ja) | 2014-06-19 |
| BR112013027851A2 (pt) | 2017-11-07 |
| CN103874526A (zh) | 2014-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200239958A1 (en) | Methods of predicting the development of complement-mediated disease | |
| Gajecka et al. | Localization of a gene for keratoconus to a 5.6-Mb interval on 13q32 | |
| Mootha et al. | Association and familial segregation of CTG18. 1 trinucleotide repeat expansion of TCF4 gene in Fuchs' endothelial corneal dystrophy | |
| Lam et al. | A genome-wide scan maps a novel high myopia locus to 5p15 | |
| US8053190B2 (en) | Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26 | |
| CN102177436B (zh) | 鉴定疾病风险因子的方法 | |
| US20210180129A1 (en) | Methods of predicting the development of amd based on chromosome 1 and chromosome10 | |
| WO2010075519A2 (en) | Allelic variants associated with advanced age-related macular degeneration | |
| US20070037183A1 (en) | Diagnostic and therapeutic target for macular degeneration | |
| US20150292016A1 (en) | Novel markers for mental disorders | |
| Kondo et al. | Role of RDBP and SKIV2L variants in the major histocompatibility complex class III region in polypoidal choroidal vasculopathy etiology | |
| US20140141432A1 (en) | Method and kit for diagnosing glaucoma in dogs | |
| Vincent et al. | Characterization of a de novo translocation t (5; 18)(q33. 1; q12. 1) in an autistic boy identifies a breakpoint close to SH3TC2, ADRB2, and HTR4 on 5q, and within the desmocollin gene cluster on 18q | |
| EP1673472B1 (en) | Use of genetic polymorphisms to predict drug-induced hepatotoxicity | |
| Sipahimalani et al. | A systematic evaluation of the ataxia telangiectasia mutated gene does not show an association with non‐Hodgkin lymphoma | |
| WO2013035861A1 (ja) | 加齢黄斑変性の易罹患性判定方法、プライマー対、プローブ、加齢黄斑変性診断キット、加齢黄斑変性の治療薬及び加齢黄斑変性の治療薬のスクリーニング方法 | |
| Wang | Gene discovery for age-related macular degeneration |